Cancer, Lung Clinical Trial
Official title:
Clinical Description of a Bronchoscopic Approach to Ablate Lung Nodules Using the Emprint™ Ablation Catheter Kit With Thermosphere™ Technology
The purpose of this investigation is to characterize the safety and performance of the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology in clinical use. This is a prospective, single-arm, multicenter, non-randomized study. Up to 3 sites in up to 3 countries will enroll up to 30 subjects in total. The study is designed to characterize the safety and performance of the bronchoscopic ablation procedure using the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology.
The primary objective of this prospective, single-arm, multicenter, non-randomized study is to characterize the safety of the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology device in subjects undergoing lung ablation procedures. The primary endpoint is the composite rate of adverse events related to the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology through 1-month follow-up. The following secondary endpoints will be evaluated: - Composite rate of serious adverse events related to the Emprint™ Ablation Catheter Kit with Thermosphere™ Technology through 1-month follow-up. - Composite rate of all adverse events related to the procedure or study devices through 1-month follow-up. - Composite rate of all serious adverse events related to the procedure or study devices through 1-month follow-up. - Patient satisfaction and pain (Bronchoscopic Ablation Patient Pain and Satisfaction Survey) - Quality of life (EQ-5D Scale) - Technical success - Technique efficacy ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06152419 -
Patient Education Videos to Improve Patients' Experience During Radiotherapy Treatment: a National Project
|
N/A | |
Recruiting |
NCT04105647 -
Lifestyle Modification Program for Lung Cancer Patients - A Pilot Study
|
N/A | |
Completed |
NCT05732350 -
Exploratory Drug Interaction Study Between SMIs and DOACs
|
||
Active, not recruiting |
NCT04300244 -
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
|
Phase 2 | |
Recruiting |
NCT05311709 -
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities
|
Phase 2 | |
Active, not recruiting |
NCT04396457 -
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
|
Phase 2 | |
Recruiting |
NCT06391749 -
Clinical Validation of an MCED Test in Symptomatic Populations (K-ACCELERATE)
|
||
Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
Recruiting |
NCT03301493 -
Genomic Testing and Resulting Medical Decisions
|
||
Completed |
NCT04788147 -
Performance and Safety of Biology-Guided Radiotherapy Using the RefleXion Medical Radiotherapy System (BIOGUIDE-X)
|
N/A | |
Not yet recruiting |
NCT06035731 -
Evaluation of the Medical Service by Socio-aesthetics in Oncology
|
N/A | |
Recruiting |
NCT03274349 -
Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma
|
N/A | |
Recruiting |
NCT05830097 -
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02991677 -
Exercise Effect on Chemotherapy-Induced Neuropathic Pain
|
N/A | |
Completed |
NCT04971304 -
Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars
|
||
Recruiting |
NCT04859400 -
Influence of a Home-based Nutrition and Exercise Program on Quality of Life of Palliative Cancer Outpatients
|
N/A | |
Recruiting |
NCT05948865 -
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04270890 -
Investigation of an Abdominal Compression Device
|
N/A | |
Not yet recruiting |
NCT05154474 -
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
|
||
Not yet recruiting |
NCT05857995 -
Precision Lung Cancer Survivorship Care Intervention
|
N/A |